Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study prospectively investigates the molecular mechanisms of primary and acquired resistance to standard-of-care BRAF V600E-directed therapy in patients with metastatic colorectal cancer and aims to pre-clinically develop novel strategies to reverse therapy resistance. Clinically approved combination treatment with cetuximab, encorafenib and chemotherapy improves patient outcomes, yet patients eventually experience disease progression. In this prospective multicenter study, tumor tissue, blood, and stool samples will be collected before treatment and at progression, to identify genetic and non-genetic mechanisms of resistance. Additionally, tumor tissue-based in vitro models (patient-derived organoids, PDOs) will be generated and exploited for functional in vitro testing, including genomic and pharmacologic perturbation studies. The overarching goal is to generate knowledge that can help develop new and more effective treatment strategies for future patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany zaawansowany rak jelita grubego z mutacją BRAF V600E, który nie da się usunąć chirurgicznie
- •Planowane rozpoczęcie leczenia kombinowanego antyterapią skierowaną na EGFR i inhibitor BRAF
- •Co najmniej jeden guz dostępny do pobrania próbki
- •Ogólny stan zdrowia pozwalający na uczestnictwo (skala ECOG 0-2)
- •Przewidywana długość życia co najmniej 3 miesiące
- •Wiek co najmniej 18 lat
- •Zdolność do podpisania świadomej zgody
✗ Disqualifies
- •Przeciwwskazania medyczne lub chirurgiczne do pobrania próbki guza
- •Inny aktywny nowotwór (oprócz raka skóry bez melanomy)
- •Niemożność wykonywania procedur badania (np. ze względu na barierę językową)
- •Ciąża lub karmienie piersią
- •Wcześniejsze leczenie inhibitorem BRAF
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
Kantonsspital Aarau
Aarau, Switzerland
Kantonsspital Baden
Baden, Switzerland
St. Claraspital
Basel, Switzerland
Universitaetsspital Basel
Basel, Switzerland
Inselspital Bern
Bern, Switzerland
Spitalzentrum Biel - MEDIN La Tour
Biel, Switzerland
Kantonsspital Graubünden
Chur, Switzerland
Luzerner Kantonsspital
Lucerne, Switzerland
HOCH Health Ostschweiz - Kantonsspital St. Gallen
Sankt Gallen, Switzerland
Bürgerspital Solothurn
Solothurn, Switzerland
HFR Freiburg - Kantonsspital
Villars-sur-Glâne, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Universitätsspital Zürich USZ
Zurich, Switzerland
Trial contact
Krista Zackel
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.